"EIPICO" affirms its superiority for the Egyptian pharmaceutical market in the first half of 2022.
August 2th, 2022
Ranked Number 1 in the local market by unit wise.
Ranked Number 1 in the Egyptian pharmaceutical exports.
Ranked Number 1 in the Egyptian Ophthalmic Market.
Ranked Number 1 in pharmaceutical production.
"IQVIA data since January till the end of June 2022 affirms EIPICO's superiority for the Egyptian pharmaceutical market". Dr. Ahmed Kelani EIPICO Chairman & Managing Director stated .
EIPICO still at the top of all Egyptian Pharmaceutical companies in the local market by unit wise with 98.5 million units, 15 % growth and 8.3 % market share by total sales 1.6 billion EGP (excluding stores' sales) & 18 % sales growth, also EIPICO has 11 products of the best-selling 100 Pharmaceutical products by units in Egypt for example (CEFOTAX – CETAL – BETADERM - FLUMOX). Dr. Kelani add
Regarding the market of ophthalmic products, EIPICO by 12.9 million units, remains ranked No.1 in the Egyptian ophthalmic market in the first half of 2022 with 63% growth, 29 % market share and 153.6 million EGP sales with 90 % sales growth. Also EIPCO has the best-selling ophthalmic product by unit ( DEXATROL ) Next to another 3 products at the top 10 ophthalmic products. Dr. Kelani add
Dr. Kelani referred EIPICO is strongly keeping its rank No.1 in the Egyptian pharmaceutical exports achieving 16 % growth with 26.4 $ million capturing 23 % of total Egyptian exports, EIPCIO is exporting to 70 Countries around the world under slogan" made in Egypt"
One of the most advanced and largest pharmaceutical factories in Egypt and middle east is standing behind all these achievements. As EIPICO produced 154.5 million units and achieved 17.7 % growth with value 1.9 billion EGP by 23 % growth, all these numbers prove that EIPCIO with ACDIMA system is the state's strong arm for providing medicines for Egyptian, Dr. Kelani concluded.